Catalog
About this item
Course/Activity Information
ACNM Webinar Series - Prostate Radioligand Therapy
Technologist Member Fee: Free; Non-Member Fee: $32.00
Physician Member Fee: Free; Non-Member Fee: $49.00
Physicist Member Fee: Free; Non-Member Fee: $40.00
Pharmacist Member Fee: Free; Non-Member Fee: $40.00
Non-Credit Member Fee: Free; Non-Member Fee: $40.00
Release Date: March 28 2024 Expiration Date: March 30 2027
Presenter
Oliver Sartor MD
Financial Disclosure
|
Name |
Role |
Disclosure |
|
Gary Ulaner MD PhD FACNM |
Organizer |
ACNM President-Elect Hoag Cancer Center Consultant Research Grant and Speaker’s Bureau for Lantheus GE Healthcare and ImaginAb |
|
Katherine Zukotynski BASc MD PhD P.Eng |
Organizer |
ACNM Vice President-Elect McMaster University Nothing to Disclose |
|
Twyla Bartel DO FACNM FSNMMI |
Organizer |
ACNM Education Committee Co-Chairperson Global Advanced Imaging PLLC Nothing to Disclose |
|
Azeem Arshad MD |
Moderator |
Nothing to Disclose |
|
Oliver Sartor MD |
Presenter |
Tulane University Consultant - Advanced Accelerator Applications Amgen ART BioScience Astellas Pharma AstraZeneca Bayer Clarity Pharmaceuticals EMD Serono Fusion Pharmaceuticals Isotopen Technologien Janssen MacroGenics Novartis Pfizer Point Biopharma Ratio Sanofi Telix Pharmaceuticals and TeneoBio. Research Grant - Advanced Accelerator Applications Amgen AstraZeneca Bayer InVitae Janssen Lantheus Merck and Sanofi; ST-AbbVie Cardinal Health Clarity Pharmaceuticals Convergent Eli Lilly Fusion Pharmaceuticals Point Biopharma Ratio Telix and United Health Group |
|
The ACNM Education Committee reviewers and SNMMI Staff have indicated that they do not have a financial interest arrangement or affiliation with any commercial organization that may have a direct or indirect interest in the content presented. |
||
|
Mark Tulchinsky MD FACNM FSNMMI |
ACNM President Penn State Health Milton S. Hershey Med. Center |
|
|
Perry Gerard MD MBA |
No affiliation ACNM Education Committee Co-Chair |
|
|
Tracy L. Yarbrough MD PhD MAEd FACNM |
California Northstate University ACNM Education Committee Co-Chair |
|
|
Ragheed Al-Dulaimi MD MPH MSc |
Hurley Medical Center ACNM Education Committee Member |
|
|
Ishani Dalal MD |
Henry Ford Hospital ACNM Education Committee Member |
|
|
Joseph S. Fotos MD |
Penn State Milton S. Hershey Medical Center ACNM Education Committee Member |
|
|
Erin Grady MD CCD FACNM |
Emory University School of Medicine ACNM Education Committee Member |
|
|
Erica J. Cohen Major DO MPH FACNM |
Edward Hines VA ACNM Education Committee Member |
|
|
Carl I. Odom MD MS |
Austin Radiological Association ACNM Education Committee Member |
|
|
Guofan Xu MD PhD |
The University of Texas MD Anderson Cancer Center ACNM Education Committee Member |
|
|
Arnold M. Strashun MD |
Chair Continuing Education Committee |
|
|
Helen Nadel MD |
CE Reviewer |
|
|
Caroline Krystek |
SNMMI Staff Education |
|
|
No Commercial Support was received for this activity |
||
In accordance with ACCME Revised Standards for Commercial Support and SNMMI Conflict-of-Interest Policy the speaker has indicated no relevant relationships that could be perceived as a real or apparent conflict of interest. Disclosure of a relationship is not intended to suggest or to condone bias but is made to provide participants with information that might be of potential importance to their evaluation of the activity.
Target Audience
Physicians physicists pharmacists and technologists
Objectives
At the completion of this activity the participant will be able to:
1. Examine the randomized clinical trial data in the pre-taxane metastatic CRPC space.
2. Discuss upcoming randomized clinical trials that are addressing castrate sensitive disease.
3. Discuss the limited data using PSMA AC-225 in the castrate-sensitive space
Continuing Education Credit Information
To receive CE credit learners must first complete the activity content achieve a score of 75% on the post-course assessment and complete the evaluation. Learners will have no more than 3 attempts to successfully complete the post-test. This activity must be completed by the expiration date listed above.